(Total Views: 607)
Posted On: 06/18/2021 4:21:08 PM
Post# of 148902
Great article and even these scientists are not sure how to design a trial for LH as the variables are so many, they too can't figure out how to design a trial and what bio-markers to use or measure being many were intubated, ECMO, Oxygen flow etc. etc and then add in a dash of non hospitalized patients who were not severe and on and on.
Now, the question is, how will or how did, I should say, did Dr. Rechnor and the others design our LH P-2 trial of the 56 patients or 28 on LL and 28 on placebo.
I just hope that CYDY has top notch bio-markers to address all these factors when they tell us the results of the unblinding on Monday. Geeeezzzzz, this could be quite interesting indeed!
Lastly, if these top scientists are not sure of how to measure all this, how can the US fda unscramble it all as CYDY will be the very first to show results even though the 56 patient trial is measured on safety alone.
Wow, I am just befuddled by this article Ganesha. So many variables it's just way above me. Maybe Ohm can chime in on this article and how CYDY my fare - GLTU and thanks for posting Ganesha
HCIT
Now, the question is, how will or how did, I should say, did Dr. Rechnor and the others design our LH P-2 trial of the 56 patients or 28 on LL and 28 on placebo.
I just hope that CYDY has top notch bio-markers to address all these factors when they tell us the results of the unblinding on Monday. Geeeezzzzz, this could be quite interesting indeed!
Lastly, if these top scientists are not sure of how to measure all this, how can the US fda unscramble it all as CYDY will be the very first to show results even though the 56 patient trial is measured on safety alone.
Wow, I am just befuddled by this article Ganesha. So many variables it's just way above me. Maybe Ohm can chime in on this article and how CYDY my fare - GLTU and thanks for posting Ganesha
HCIT
(5)
(1)Scroll down for more posts ▼
